Short answer
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $34M with net income of −$6M.
Q2 2026 key financials · XBRL
- Revenue
- $34M
- +47.3% QoQ
- Net income
- −$6M
- +58.9% QoQ
- Operating margin
- 7.5%
- Gross margin
- 35.3%
- EPS (diluted)
- −$0.18
- +58.1% QoQ
Source: XBRL data from the LIFECORE BIOMEDICAL, INC. DE (LFCR) Q2 2026 10-Q on SEC EDGAR. USD.
LIFECORE BIOMEDICAL, INC. DE Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $34.167M, down 6% YoY from $36.444M
- Gross margin 35.3% vs 38.4% YoY
- HA manufacturing best performer: revenue $18.615M, up 44%; CDMO worst: $15.552M, down 34%
- Cash $17.2M plus $21.6M borrowing availability; no revolving debt outstanding
- Outlook: over 40 cost-reduction projects; headwinds include rising Alcon loan interest and customer project timing
Risk Factors
- No new regulatory, legal, compliance, operational, competitive, market, or financial risks identified
- No director or executive adopted or terminated trading arrangements during three months ended June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LIFECORE BIOMEDICAL, INC. DE quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.